SS-31

SS-31 (elamipretide, formerly Bendavia/MTP-131) is a synthetic tetrapeptide that selectively targets the inner mitochondrial membrane. Developed by Hazel Szeto at Weill Cornell Medical College, it is the lead compound in a class of mitochondria-targeted peptides (Szeto-Schiller peptides) designed to restore mitochondrial function in aging and disease. The peptide carries a 3+ charge at physiological pH due to its D-arginine and lysine residues, which drives its rapid, energy-independent accumulation in mitochondria at concentrations 1,000-5,000 fold greater than in the cytoplasm.

Elamipretide is in clinical development by Stealth BioTherapeutics for several mitochondrial diseases, including Barth syndrome, primary mitochondrial myopathy, and age-related macular degeneration. It represents a fundamentally different approach to antioxidant therapy — rather than scavenging reactive oxygen species after they form, SS-31 optimizes mitochondrial electron transport to prevent excessive ROS generation at the source. This mechanism has generated interest in the anti-aging research community, as mitochondrial dysfunction is a hallmark of cellular aging.

SS-31 selectively binds to cardiolipin, an anionic phospholipid found exclusively in the inner mitochondrial membrane where it constitutes approximately 20% of total lipid content. Cardiolipin is essential for the structural organization and function of electron transport chain (ETC) complexes and ATP synthase. With aging and in disease states, cardiolipin undergoes peroxidation and remodeling that disrupts ETC complex interactions, increases electron leak, and promotes excessive ROS generation.

SS-31 binds to cardiolipin through electrostatic and hydrophobic interactions, stabilizing the cristae architecture and optimizing the interaction between ETC complexes. This does not require the peptide to scavenge free radicals directly — instead, it improves the efficiency of electron transfer from Complex I/II through Complex III to Complex IV, reducing the probability of electron leak to molecular oxygen. The net effect is reduced superoxide generation, preserved mitochondrial membrane potential, improved ATP synthesis, and reduced cytochrome c release (a trigger for apoptosis). The D-amino acid (D-Arg) and dimethyltyrosine (Dmt) residues confer resistance to proteolytic degradation, giving the tetrapeptide a functional half-life that exceeds what its size would suggest.